CRISPR NEWS

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR/Cas9 Genome Editing Technology” September 10, 2018

CRISPR Therapeutics, Intellia Therapeutics and Caribou Biosciences Provide Update on U.S Court of Appeals for the Federal Circuit Decision Upholding the Ruling by U.S. Patent and Trademark Office in Interference Proceeding Relating to CRISPR-Cas9 Genome Editing Technology

On September 10, 2018 the U.S. Court of Appeals for the Federal Circuit affirmed the decision by the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board in an interference proceeding relating to CRISPR-Cas9 genome editing technology. The interference was requested by CVC, co-owners of foundational intellectual property relating to CRISPR/Cas9 genome engineering, against the Broad Institute, Harvard University and the Massachusetts Institute of Technology.

View Press Release

LATEST

Sign up to receive updates from the CRISPR Collective

Related News

U.S. Patent and Trademark Office issues 9th and 10th CRISPR patents to CVC July 23, 2019
U.S. Patent and Trademark Office issues 8th CRISPR patent to CVC July 16, 2019
U.S. Patent and Trademark Office issues 7th CRISPR patent to CVC July 2, 2019
Read moreArrow-down